Clinical trials: Estrogen Therapy
Breast Cancer
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women
The purpose of this study is to assess clinical outcomes after Letrozole treatment according to the estrogen receptor expression in postmenopausal women with hormone receptor positive breast cancer.
- Trial name
- LETTER (NCT01069211)
- Where
- South Korea
- Volunteers
- 876 people
- Sponsor
- Korean Breast Cancer Study Group
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Atherosclerosis, Healthy
Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls
This study will determine the effects of hormone replacement therapy (estrogen alone or estrogen and progesterone) on the walls of arteries in postmenopausal women.
- Conditions
- Atherosclerosis, Healthy, Vascular Disease
- Trial name
- NCT00005108
- Testing
- Estradiol, Progesterone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Healthy
Estrogen Alternatives Study
Healthy postmenopausal women not currently taking hormone replacement or hormone modulating therapy take a 3-month course of estradiol/raloxifene/placebo to evaluate the effects of each on vascular function, as indicated by PET…
- Trial name
- NCT00108238
- Testing
- Estradiol followed by progesterone, Raloxifene
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Polyostotic Fibrous Dysplasia, Precocious Puberty
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
The normal changes of puberty, such as breast enlargement, pubic hair and menstrual periods, usually begin between the ages of 9 and 15 in response to hormones produced in the body.
- Trial name
- NCT00001181
- Testing
- Testolactone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Systemic Lupus Erythematosus
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
The first part of this study will use the database of a large, ongoing NIH-sponsored lupus study, Safety of Estrogen in Lupus Erythematosus National Assessment.
- Trial name
- SACS-SLE (NCT00000421)
- Testing
- Prednisone
- Where
- 3 sites in United States
- Volunteers
- 154 people
- Sponsor
- NYU Langone Health
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Amenorrhea
Retrospective Observational Evaluation of the Bone Mineral Density Outcome in Young Women With Amenorrhea
The study aims to evaluate the outcomes of different estrogen therapy regimens in patients with amenorrhea who face prolonged periods of hypoestrogenism.
- Trial name
- NCT07015476
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer, Musculoskeletal Complications
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy
RATIONALE: Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone…
- Conditions
- Breast Cancer, Musculoskeletal Complications, Pain
- Trial name
- NCT01598298
- Testing
- duloxetine hydrochloride
- Where
- 714 sites in United States
- Volunteers
- 299 people
- Sponsor
- SWOG Cancer Research Network
Postmenopausal Period, Osteoporosis, Postmenopausal
Angeliq Regulatory Post Marketing Surveillance
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA).
- Trial name
- Angeliq rPMS (NCT01064453)
- Testing
- E2/DRSP (Angeliq, BAY86-4891)
- Where
- South Korea
- Volunteers
- 4,078 people
- Sponsor
- Bayer
Sleep Disorders
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances
The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT).
- Trial name
- NCT00000380
- Testing
- GHRH
- Sponsor
- University of Washington
Osteoporosis
Phase III Randomized Study of the Effect of Postmenopausal Estrogen Replacement Therapy on Alveolar Bone Loss
OBJECTIVES: I. Quantify periodontal alveolar bone loss rates in postmenopausal women. II. Evaluate the effects of estrogen on alveolar bone loss rates in these patients. III.
- Trial name
- NCT00004650
- Testing
- conjugated estrogens, Medroxyprogesterone
- Volunteers
- 150 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Endometrial Cancer
Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer
RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence.
- Trial name
- NCT00002976
- Testing
- conjugated estrogens
- Where
- 149 sites in United States
- Volunteers
- 2,108 people
- Sponsor
- Gynecologic Oncology Group
Depressive Disorder, Mood Disorder
Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)
Often women are prescribed hormone replacement therapy (HRT) during the perimenopause or menopause. Hormone replacement therapy includes both estrogen and progesterone.
- Conditions
- Depressive Disorder, Mood Disorder, Psychomotor Agitation
- Trial name
- NCT00001770
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Osteoporosis, Turner's Syndrome
Hormone Replacement Therapy to Treat Turner Syndrome
This study will evaluate the effects of hormone replacement therapy on patients with Turner syndrome (TS)-a genetic disorder in females in which part or all of one X chromosome is missing.
- Trial name
- NCT00013546
- Testing
- TMTDS
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Breast Cancer
Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study
The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.
- Trial name
- NCT00255463
- Testing
- Anastrazole, Gefitinib
- Where
- 34 sites in Czechia, France and 5 more
- Volunteers
- 185 people
- Sponsor
- AstraZeneca
Primary Ovarian Insufficiency
Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
This pilot study will observe the progression of newly diagnosed POI patients physical and psychology outcomes after initiating standard of care HRT treatment in comparison to healthy female control participants' physical and…
- Trial name
- NCT03568708
- Testing
- Transdermal Estrogen
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Overactive Bladder
Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity
Despite the great number of reports about the efficacy of oestrogens or antimuscarinics on OAB symptoms, so far no author has tried to investigate whether the concomitant administration of these two drugs, acting on two different…
- Trial name
- NCT00648310
- Testing
- Tolterodine 4 mg, arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
- Where
- Italy
- Sponsor
- Università degli Studi dell'Insubria
Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive…
- Trial name
- FACT (NCT00256698)
- Testing
- Fulvestrant, Anastrozole
- Where
- 85 sites in Canada, Costa Rica and 10 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Menopause, Postmenopausal Vaginal Atrophy
Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency
This study is conducted in Europe. The aim of this study is to investigate the self-reported impact of Vagifem® (estradiol) treatment on urogenital discomfort in women with atrophic vaginitis due to oestrogen deficiency.
- Trial name
- NCT01507454
- Testing
- estradiol, 25 mcg
- Where
- Germany
- Volunteers
- 1,613 people
- Sponsor
- Novo Nordisk A/S